Phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of the combination of capmainib (INC280) and spartalizumab (PDR001) versus capmayinib and placebo as first-line treatment in patients with cancer.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: II
- Execution start: 12/02/2021
- End of execution: 30/01/2032
- IP: JAVIER VALDIVIA BAUTISTA